Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) is anticipated to announce its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of $0.17 per share and revenue of $86.7240 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 3, 2025 at 9:00 AM ET.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.14. The firm had revenue of $103.14 million for the quarter, compared to analysts’ expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. On average, analysts expect Verona Pharma PLC American Depositary Share to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Verona Pharma PLC American Depositary Share Price Performance

NASDAQ:VRNA opened at $106.91 on Friday. The company has a market capitalization of $9.21 billion, a P/E ratio of -107.99 and a beta of 0.05. The business’s 50-day moving average is $106.54 and its 200 day moving average is $94.35. The company has a current ratio of 10.71, a quick ratio of 10.54 and a debt-to-equity ratio of 0.87. Verona Pharma PLC American Depositary Share has a 12 month low of $31.09 and a 12 month high of $106.93.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Piper Sandler lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Zacks Research raised shares of Verona Pharma PLC American Depositary Share to a “hold” rating in a research note on Friday, August 8th. Wells Fargo & Company cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and decreased their target price for the company from $138.00 to $107.00 in a research report on Thursday, July 10th. Canaccord Genuity Group lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price target for the company. in a research report on Wednesday, July 9th. Finally, Wolfe Research downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $109.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VRNA. Geneos Wealth Management Inc. lifted its stake in shares of Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock worth $40,000 after acquiring an additional 193 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Verona Pharma PLC American Depositary Share in the first quarter worth $48,000. NewEdge Advisors LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter worth $58,000. Keel Point LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter worth $207,000. Finally, Tidal Investments LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at $373,000. Institutional investors own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.